“This programmatic update is meant to provide a current perspective for countries on the important changes and new considerations arising since publication of WHO’s PMTCT ARV guidelines, 2010 version, especially as a number of countries are now preparing to adopt Option B+. Recent developments suggest that substantial clinical and programmatic advantages can come from adopting a single, universal regimen both to treat HIV-infected pregnant women and to prevent mother-to-child transmission of HIV. This streamlining should maximize PMTCT
programme performance through better alignment and linkages with antiretroviral therapy (ART) programmes at every level of service delivery. One of WHO’s two currently recommended PMTCT antiretroviral (ARV) programme options, Option B, takes this unified approach.”
SUBMIT A RESOURCE
Share your work—including curriculum, tools, case studies, and published articles—with the OVC community.